Monoamine theories of depression: Historical impact on biomedical research

Journal of the History of the Neurosciences

Volumn 21, Issue 4, 2012, Pages 366-392

  Mulinari, Shai ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

bibliometrics; biological psychiatry; depression; history; monoamine hypothesis; monoamine theory; NIMH; Psychobiology of Depression Program

Indexed keywords

BIOGENIC AMINE;

BIBLIOMETRICS; DEPRESSION; EUROPE; HISTORY; HUMAN; MEDICAL RESEARCH; NATIONAL HEALTH ORGANIZATION; PSYCHIATRY; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL THEORY; PUBLISHING; REVIEW; RISK FACTOR; UNITED STATES;

BIBLIOMETRICS; BIOGENIC MONOAMINES; BIOMEDICAL RESEARCH; DEPRESSION; EUROPE; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; NATIONAL INSTITUTE OF MENTAL HEALTH (U.S.); PSYCHIATRY; PSYCHOLOGICAL THEORY; PUBLISHING; RISK FACTORS; UNITED STATES;

EID: 84866302252     PISSN: 0964704X     EISSN: 17445213     Source Type: Journal    
DOI: 10.1080/0964704X.2011.623917     Document Type: Review

References (85)

1. Agresti, A. 2007. An introduction to categorical data analysis, Hoboken: Wiley.
2. Agurell, S. 1981. Biogenic amines and depression (introduction to symposium). Acta Psychiatrica Scandinavica Supplementum, 290: 17-19. (Pubitemid 11156097)
3. Angst, J. 1970. Clinical aspects of imipramine, Edited by: Angst, J and Theobald, W. Tofranil, Bern: Stampfli and Cie.
4. Ashcroft, GW, Blackbur, IM, Walter, DS, Shields, PJ, Murray, LG, Glen, AIM, Eccleston, D, Crawford, TB, Connecha, J, Lonergan, M, and, Pullar, IA. 1972. Modified amine hypothesis for etiology of affective illness. The Lancet, 2 (7777): 573-577.
5. Ashcroft, GW, Crawford, TB, Eccleston, D, Sharman, DF, MacDougall, EJ, Stanton, JB, and, Binns, JK. 1966. 5-hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological diseases. The Lancet, 2 (7472): 1049-1052.
6. Axelrod, J, Whitby, LG, and, Hertting, G. 1961. Effect of psychotropic drugs on the uptake of H3-norepinephrine by tissues. Science, 133: 383-384.
7. Baldessarini, RJ. 1972. Biogenic amines and behavior. Annual Review of Medicine, 23 (5): 343-354.
8. Baldessarini, RJ. 1975. The basis for amine hypotheses in affective disorders. A critical evaluation. Archives of General Psychiatry, 32 (9): 1087-1093.
9. Ban, TA. 1987. Prolegomenon to the clinical prerequisite: psychopharmacology and the classification of mental disorders. Progress in Neuropsychopharmacology and Biological Psychiatry, 11 (5): 527-580.
10. Ban, TA. 1998. Neuropsychopharmacology and the history of pharmacotherpy in psychiatry: A review of developments in the 20th century. In The history of psychopharmacology and the CINP as told in autobiography, Edited by: Ban, TA, Healy, D and Shorter, E. CINP vol 1.
11. Baumeister, AA, and, Hawkins, MF. 2004. The serotonin hypothesis of schizophrenia: a historical case study on the heuristic value of theory in clinical neuroscience. Journal for the History of the Neurosciences, 13 (3): 277-291. (Pubitemid 39473018)
12. Baumeister, AA, Hawkins, MF, and, Uzelac, SM. 2003. The myth of reserpine-induced depression: role in the historical development of the monoamine hypothesis. Journal for the History of the Neurosciences, 12 (2): 207-220. (Pubitemid 36944203)
13. Barsa, JA, and, Kline, NS. 1957. Depression treated with chlorpromazine and promethazine. American Journal of Psychiatry, 113 (8): 744-745.
14. Berlucchi, G, and, Buchtel, HA. 2009. Neuronal plasticity: historical roots and evolution of meaning. Experimental Brain Research, 192 (3): 307-319.
15. Bertilsson, LM, sberg, M, and, Thorén, P. 1974. Differential effect of chlorimipramine and nortriptyline on cerebrospinal fluid metabolites of serotonin and noradrenalinee in depression. European Journal of Clinical Pharmacology, 7 (5): 365-368.
16. Bunney, WE, and, Davis, JM. 1965. Norepinephrine in depressive reactions-a review. Archives of General Psychiatry, 13 (6): 483-494.
17. Carlsson, A. 2010. Interview with author. Lund, Sweden. 2010-11-15
18. Carlsson, A, Corrodi, H, Fuxe, K, and, Hokfelt, T. 1969a. Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-alpha-ethyl-meta-tyramine. European Journal of Clinical Pharmacology, 5 (4): 357-366.
19. Carlsson, A, Corrodi, H, Fuxe, K, and, Hokfelt, T. 1969b. Effects of some antidepressant drugs on depletion of intraneuronal brain catecholamine stores caused by 4,alpha-dimethyl-meta-tyramine. European Journal of Clinical Pharmacology, 5 (4): 367-373.
20. Carlsson, A, Fuxe, K, and, Ungerstedt, U. 1968. The effect of imipramine on central 5-hydroxytryptamine neurons. Journal of Pharmacy and Pharmacology, 20 (2): 150-151.
21. Carlsson, A, and, Healy, D. 1996. The rise of Neuropsychopharmacology: impact on basic and clinical neuroscience. In The psychopharmacologists I: interviews by David Healy, 51-80. London: Chapman and Hall.
22. Carlsson, A, Lindqvist, M, and, Magnusson, T. 1957. 3,4- Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature, 180 (4596): 1200
23. Carlsson, A, Lindqvist, M, Magnusson, T, and, Waldeck, B. 1958. On the presence of 3-hydroxytyramine in brain. Science, 127 (3296): 471
24. Charney, DS, Menkes, DB, and, Heninger, GR. 1981. Receptor sensitivity and the mechanism of action of antidepressant treatment. Implications for the etiology and therapy of depression. Archives of General Psychiatry, 38 (10): 1160-1180. (Pubitemid 11013060)
25. Coppen, A. 1967. The biochemistry of affective disorders. British Journal of Psychiatry, 113 (504): 1237-1264.
26. Coppen, A, Shaw, DM, and, Farrell, JP. 1963. Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. The Lancet, 1 (7272): 79-81.
27. Coppen, A, Whybrow, PC, Noguera, R, and, Prange, AJ. 1972. Abnormalities of indoleamines in affective disorders. Archives of General Psychiatry, 26 (5): 474-478.
28. Davies, DL, and, Shepherd, M. 1955. Reserpine in the treatment of anxious and depressed patients. The Lancet, 269 (6881): 117-120.
29. Denber, HC, and, Bird, EG. 1956. Chlorpromazine in the treatment of mental illness. III. The problem of depression. American Journal of Psychiatry, 112 (12): 1021
30. Dencker, SJ, Malm, U, Roos, BE, and, Werdinius, B. 1966. Acid monoamine metabolites of cerebrospinal fluid in mental depression and mania. Journal of Neurochemistry, 13 (12): 1545-1548.
31. Duman, RS, Heninger, GR, and, Nestler, EJ. 1997. A molecular and cellular theory of depression. Archives of General Psychiatry, 54 (7): 597-606. (Pubitemid 27306570)
32. Eccleston, D, and, Healy, D. 2000. The receptor enters psychiatry (2). In The psychopharmacologists III: Interviews by David Healy London, Arnold: pp. 201-212
33. Everett, GM, and, Toman, JEP. 1959. Mode of action of Rauwolfia alkaloids and motor activity. In Biological Psychiatry. Proceedings of the Scientific Sessions of the Society of Biological Psychiatry San Francisco, May 1958, Edited by: Masserman, JH. 75-81. New York: Grune & Stratton.
34. Glowinski, J, and, Axelrod, J. 1964. Inhibition of uptake of tritiated-noradrenalinee in the intact rat brain by imipramine and structurally related compounds. Nature, 204: 1318-1319.
35. Gluckman, MI, and, Baum, T. 1969. The pharmacology of iprindole, a new antidepressant. Psychopharmacologia, 15 (3): 169-185.
36. Goodlet, I, Mireylees, SE, and, Sugrue, MF. 1977. Effects of mianserin, a new antidepressant, on the in vitro and in vivo uptake of monoamines. British Journal of Pharmacology, 61 (2): 307-313. (Pubitemid 8165418)
37. Healy, D. 1997. The antidepressant era, Cambridge: MA, Harvard University Press.
38. Holden, C. 1991. Depression: the news isn't depressing. Science, 254 (5037): 1450-1452.
39. Hyman, SE, and, Nestler, EJ. 1996. Initiation and adaptation: a paradigm for understanding psychotropic drug action. American Journal of Psychiatry, 153 (2): 151-162. (Pubitemid 26038955)
40. Katz, MM. 2000. The Role of Methodology and Collaborative Studies in Psychopharmacologic Research. In: Ban TA, Healy D, Shorter E. The history of psychopharmacology and the CINP as told in autobiography. CINP, 2: 284-290.
41. Katz, MM, and, Friedman, RJ. 1974. The psychology of depression: contemporary theory and research, Oxford: John Wiley & Sons.
42. Katz, MM, Secunda, SK, Hirschfeld, RM, and, Koslow, SH. 1979. NIMH clinical research branch collaborative program on the psychobiology of depression. Archives of General Psychiatry, 36 (7): 765-771. (Pubitemid 10102539)
43. Keating, P, and, Cambrioso, A. 2003. Biomedical platforms, Cambridge, MA: MIT Press.
44. Keller, EF. 1995. Refiguring life: metaphors of twentieth-century biology, New York: Columbia Univ. Press.
45. Keller, EF. 2000. The century of the gene, Cambridge, MA: Harvard Univ. Press.
46. Klein, DF, and, Davis, JM. 1969. Diagnosis and drug treatment of psychiatric disorders, Baltimore: Williams & Wilkins Co.
47. Klerman, GL, and, Cole, JO. 1965. Clinical Pharmacology of Imipramine and Related Antidepressant Compounds. Pharmacological Reviews, 17: 101-141.
48. Klein, DF, and, Healy, D. 1996. Reaction patterns, psychotropic drugs and the discovery of panic disorder. In The psychopharmacologists: Interviews by David Healy, 329-352. London: Chapman and Hall.
49. Kline, NS. 1954. Use of Rauwolfia serpentina beth. in neuropsyciatric conditions. Annals of the New York Academy of Sciences, 59 (1): 107-132.
50. Koslow, SH, Maas, JW, Bowden, CL, Davis, JM, Hanin, I, and, Javaid, J. 1983. CSF and urinary biogenic amines and metabolites in depression and mania. A controlled, univariate analysis. Archives of General Psychiatry, 40 (9): 999-1010. (Pubitemid 13049076)
51. Krishnan, V, and, Nestler, EJ. 2008. The molecular neurobiology of depression. Nature, 455 (7215): 894-902.
52. Lacasse, JR, and, Leo, J. 2005. Serotonin and depression: a disconnect between the advertisements and the scientific literature. PLoS Medicine, 2 (12): e392
53. Lapin, IP, and, Oxenkrug, GF. 1969. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. The Lancet, 1 (7586): 132-136.
54. Maas, JW. 1975. Biogenic amines and depression. Biochemical and pharmacological separation of two types of depression. Archives of General Psychiatry, 32 (11): 1357-1361.
55. Maas, JW, Fawcett, JA, and, Dekirmenjian, H. 1972. Catecholamine metabolism, depressive illness, and drug response. Archives of General Psychiatry, 26 (3): 252-262.
56. Maas, JW, Kocsis, JH, Bowden, CL, Davis, JM, Redmond, DE, Hanin, I, and, Robins, E. 1982. Pre-treatment neurotransmitter metabolites and response to imipramine or amitriptyline treatment. Psychological Medicine, 12 (1): 37-43. (Pubitemid 12126794)
57. Maas, JW, Koslow, SH, Davis, JM, Katz, MM, Mendels, J, Robins, E, Stokes, PE, and, Bowden, CL. 1980. Biological component of the NIMH clinical research branch collaborative program on the psychobiology of depression: I. Background and theoretical considerations. Psychological Medicine, 10 (4): 759-776.
58. Maas, JW, Koslow, SH, Katz, MM, Bowden, CL, Gibbons, RL, Stokes, PE, Robins, E, and, Davis, JM. 1984. Pretreatment neurotransmitter metabolite levels and response to tricyclic antidepressant drugs. American Journal of Psychiatry, 141 (10): 1159-1171. (Pubitemid 14011485)
59. Mendels, J, and, Frazer, A. 1974. Brain biogenic amine depletion and mood. Archives of General Psychiatry, 30 (4): 447-451.
60. Moed, HF. 2005. Citation analysis in research evaluation, Dordrecht: Springer.
61. Moncrieff, J. 2008. The creation of the concept of an antidepressant: an historical analysis. Social Science & Medicine, 66 (11): 2346-2355. (Pubitemid 351608724)
62. Pare, CM, and, Sandler, M. 1959. A clinical and biochemical study of a trial of iproniazid in the treatment of depression. Journal of Neurology, Neurosurgery & Psychiatry, 22: 247-251.
63. Peet, M, and, Behagel, H. 1978. Mianserin: a decade of scientific development. British Journal of Clinical Pharmacology, 5 (Supplement 1): 5S-9S. (Pubitemid 8272665)
64. Post, RM. 1997. Molecular biology of behavior. Targets for therapeutics. Archives of General Psychiatry, 54 (7): 607-608.
65. Rosenberg, CE. 2006. Contested boundaries: psychiatry, disease, and diagnosis. Perspectives in Biology and Medicine, 49 (3): 407-424. (Pubitemid 44106890)
66. Rosloff, BN, and, Davis, JM. 1974. Effect of iprindole on norepinephrine turnover and transport. Psychopharmacologia, 40 (1): 53-64.
67. Schildkraut, JJ. 1965. The catecholamine hypothesis of affective disorders: a review of supporting evidence. American Journal of Psychiatry, 122 (5): 509-522.
68. Schildkraut, JJ. 1995. The catecholamine hypothesis of affective disorders: a review of supporting evidence. 1965. Journal of Neuropsychiatry & Clinical Neurosciences, 7 (4): 524-533. discussion 523-524
69. Schildkraut, JJ, and, Healy, D. 2000. The catecholamine hypothesis. In The psychopharmacologists III: Interviews by David Healy, 111-134. London: Arnold.
70. Schildkraut, JJ, and, Kety, SS. 1967. Biogenic amines and emotion. Science, 156 (771): 21-37.
71. Secunda, S, Koslow, SH, Redmond, DE, Garver, D, Ramsey, TA, Croughan, J, Kocsis, J, Hanin, I, Lieberman, K, and, Casper, R. 1980. Biological component of the NIMH clinical research branch collaborative program on the psychobiology of depression: II. Methodology and data analysis. Psychological Medicine, 10 (4): 777-793.
72. Shorter, E. 1997. A history of psychiatry, New York: John Wiley & Sons.
73. Shorter, E. 2009. Before Prozac, Oxford: Oxford University Press.
74. Spiker, DG, Edwards, D, Hanin, I, Neil, JF, and, Kupfer, DJ. 1980. Urinary MHPG and clinical response to amitriptyline in depressed patients. American Journal of Psychiatry, 137 (10): 1183-1187. (Pubitemid 10015063)
75. Stahl, SM. 1984. Regulation of neurotransmitter receptors by desipramine and other antidepressant drugs: the neurotransmitter receptor hypothesis of antidepressant action. Journal of Clinical Psychiatry, 45 (10 Pt 2): 37-45. (Pubitemid 14008077)
76. Stokes, PE, Stoll, PM, Koslow, SH, Maas, JW, Davis, JM, Swann, AC, and, Robins, E. 1984. Pretreatment DST and hypothalamic-pituitary-adrenocortical function in depressed patients and comparison groups. A multicenter study. Archives of General Psychiatry, 41 (3): 257-267. (Pubitemid 14168079)
77. Udenfriend, S, Weissbach, H, and, Bogdanski, DF. 1957. Effect of iproniazid on serotonin metabolism in vivo. Journal of Pharmacology and Experimental Therapeutics, 120 (2): 255-260.
78. van Praag, H., and, Healy, D. 1996. Psychiatry and the march of folly. In The psychopharmacologists: Interviews by David Healy, 353-380. London: Chapman and Hall.
79. Vetulani, J, and, Sulser, F. 1975. Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature, 257 (5526): 495-496.
80. Wilson, M. 1993. DSM-III and the transformation of American psychiatry: a history. American Journal of Psychiatry, 150 (3): 399-410.
81. Wong, DT, Horng, JS, Bymaster, FP, Hauser, KL, and, Molloy, BB. 1974. A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p- trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sciences, 15 (3): 471-479.
82. Zeller, E, Barsky, J, Fouts, J, Kirchheimer, W, and, Orden, L. 1952. Influence of isonicotinic acid hydrazide (INH) and 1-isonicotinyl-2-isopropyl hydrazide (IIH) on bacterial and mammalian enzymes. Cellular and Molecular Life Sciences, 8 (9): 349-350.
83. Zis, AP, and, Goodwin, FK. 1979. Novel antidepressants and the biogenic amine hypothesis of depression. The case for iprindole and mianserin. Archives of General Psychiatry, 36 (10): 1097-1107. (Pubitemid 10118066)
84. sberg, M, Bertilsson, LM, Tuck, D, Cronholm, B, and, Sjqvist, F. 1973. Indoleamine metabolites in the cerebrospinal fluid of depressed patients before and during treatment with nortriptyline. Clinical Pharmacology & Therapeutics, 14 (2): 277-286.
85. sberg, M, Trskman, L, and, Thorén, P. 1976. 5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor?. Archives of General Psychiatry, 33 (10): 1193-1197.